Sitaxa M 50/1000mg Tablet 15s
₹197.44
Estimate Delivery by -
SITAXA M 50+1000 TABLET is used to control blood sugar levels in patients with type II diabetes mellitus, along with proper diet and exercise. It is a combination of Metformin and Sitagliptin, which belongs to the group of medicines called Antidiabetic agents.
Before taking SITAXA M 50+1000 TABLET, inform your doctor if you have any liver, kidney, or heart problems. You must also inform your doctor if you have high blood cholesterol levels, severe systemic infections, or are severely dehydrated due to excessive vomiting or diarrhea recently. During therapy with SITAXA M 50+1000 TABLET, your doctor might regularly monitor your blood sugar levels and kidney functions to avoid the risk of unwanted side effects. You may asked to make certain lifestyle changes, such as following a healthy diet, regular physical exercise, and quitting alcohol consumption, to achieve better results.
SITAXA M 50+1000 TABLET is not recommended for use in patients with severe, uncontrollable diabetes. It is also not suitable for use in patients with alcoholism, shock, or problems with breathing or blood circulation. Consult your doctor before taking SITAXA M 50+1000 TABLET if you are pregnant or breastfeeding. The most common side effects of taking SITAXA M 50+1000 TABLET are low blood sugar levels, stomach upset, constipation, flatulence, metallic taste in the mouth, sore throat, stuffy nose, and joint pain. Consult your doctor if they bother you.
Uses:
- Used to manage type II diabetes mellitus
Directions of Use
SITAXA M 50+1000 TABLET is an antidiabetic medicine. It contains two medicines, namely metformin and sitagliptin. Metformin makes the body more sensitive to insulin (a hormone involved in glucose metabolism). This helps our body cells utilize more of the circulating blood glucose. Additionally, it can stop glucose production by the liver and reduce its absorption in the body. Sitagliptin inhibits DPP-4 which leads to increased levels of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide(GIP), decreased levels of glucagon, and a stronger insulin response to glucose.
